Mega Lifesciences Public Company Limited (MEGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA) has a cash flow conversion efficiency ratio of 0.046x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (฿461.26 Million ≈ $14.38 Million USD) by net assets (฿9.95 Billion ≈ $310.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Mega Lifesciences Public Company Limited's balance sheet to measure how much of total assets are equity-financed.
Mega Lifesciences Public Company Limited - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Mega Lifesciences Public Company Limited earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Mega Lifesciences Public Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elopak AS
OL:ELO
|
0.054x |
|
Prosegur Cash S.A
MC:CASH
|
0.233x |
|
ZEAL Network SE
XETRA:TIMA
|
0.163x |
|
ARIZONA SONORAN COPPER
F:H6F
|
0.013x |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
0.009x |
|
Luye Pharma Group Ltd
F:LUP
|
0.019x |
|
AMC Entertainment Holdings Inc
NYSE:AMC
|
0.067x |
|
Cascades Inc.
TO:CAS
|
0.010x |
Annual Cash Flow Conversion Efficiency for Mega Lifesciences Public Company Limited (2011–2024)
The table below shows the annual cash flow conversion efficiency of Mega Lifesciences Public Company Limited from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Mega Lifesciences Public Company Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ฿9.88 Billion ≈ $307.85 Million |
฿2.40 Billion ≈ $74.85 Million |
0.243x | +17.40% |
| 2023-12-31 | ฿9.30 Billion ≈ $289.94 Million |
฿1.93 Billion ≈ $60.05 Million |
0.207x | -8.96% |
| 2022-12-31 | ฿8.78 Billion ≈ $273.56 Million |
฿2.00 Billion ≈ $62.23 Million |
0.227x | -33.05% |
| 2021-12-31 | ฿8.03 Billion ≈ $250.14 Million |
฿2.73 Billion ≈ $84.99 Million |
0.340x | +45.53% |
| 2020-12-31 | ฿6.98 Billion ≈ $217.53 Million |
฿1.63 Billion ≈ $50.79 Million |
0.233x | -3.57% |
| 2019-12-31 | ฿6.18 Billion ≈ $192.47 Million |
฿1.50 Billion ≈ $46.60 Million |
0.242x | +50.75% |
| 2018-12-31 | ฿5.72 Billion ≈ $178.42 Million |
฿919.36 Million ≈ $28.66 Million |
0.161x | -9.14% |
| 2017-12-31 | ฿5.24 Billion ≈ $163.46 Million |
฿927.00 Million ≈ $28.89 Million |
0.177x | -34.37% |
| 2016-12-31 | ฿4.68 Billion ≈ $145.87 Million |
฿1.26 Billion ≈ $39.29 Million |
0.269x | +91.67% |
| 2015-12-31 | ฿4.33 Billion ≈ $135.11 Million |
฿609.12 Million ≈ $18.99 Million |
0.141x | -8.98% |
| 2014-12-31 | ฿3.98 Billion ≈ $124.00 Million |
฿614.22 Million ≈ $19.14 Million |
0.154x | +22.40% |
| 2013-12-31 | ฿3.69 Billion ≈ $115.09 Million |
฿465.77 Million ≈ $14.52 Million |
0.126x | -40.02% |
| 2012-12-31 | ฿1.63 Billion ≈ $50.69 Million |
฿342.02 Million ≈ $10.66 Million |
0.210x | +3.97% |
| 2011-12-31 | ฿1.32 Billion ≈ $41.09 Million |
฿266.67 Million ≈ $8.31 Million |
0.202x | -- |
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more